Remarkably, the twofold increase in the median PFS between CDH18-positive and CDH18-negative patients with WD/DDLS is comparable in magnitude to the twofold increase in the duration of response in HR + , Her2− breast cancer patients treated with letrozole and palbociclib. Here, CDH18 is linked to breast cancer.